BACKGROUND Long-term benefits of coronary stenosis treatment with an everolimus-eluting bioresorbable
B
ioresorbable scaffolds are novel treatments for coronary stenosis that provide transient vessel support with drug-delivery capability, but without the long-term limitations of metallic drug-eluting stents. By liberating the coronary artery from the metallic caging, the vessel is able to recover pulsatility and to remodel in response to shear and wall stress, physiological cyclic strain, and pharmacological agents (1, 2) .
Nevertheless, bioresorbable scaffolds face multiple potential challenges that justify careful and longterm evaluation of this novel technology. First, the polymeric scaffolds have to match the mechanical properties of metallic stents. It has been demonstrated that the acute recoil of the novel scaffold was not inferior to that observed with an equivalent metallic device (3, 4) . Second, it has been established that mechanical integrity and the absence of recoil were maintained over a 6-month period (4) . During that time, the biological process of restenosis, consisting of neointimal formation and constrictive remodeling, ceases, and therefore, the implantation of a permanent metallic prosthesis seems unjustified (5, 6) . In the following months, physiological and pharmacological vasomotion reappear, confirming that the scaffold has lost its mechanical integrity (7) .
The polymer is then progressively replaced by a malleable provisional matrix of proteoglycan, which does not impart any loss in scaffold area (8) . On the contrary, at that stage, the malleable and dismantling scaffold can enlarge to accommodate the neointimal growth observed in the first 3 years. The ultimate integration of the scaffold into the vessel wall results from the de novo ingrowth of connective tissue into the proteoglycan matrix (9, 10) .
Rarely has a novel revascularization technique been so intensively scrutinized during the early days of its development, and the sequential assessment over 5 years provides new observations that have paved the way to large randomized trials (11) . The ultimate expectation of this novel technology is the maintenance of the lumen area, or even occurrence of late lumen enlargement, associated with wall thinning and adaptive remodeling (2) . STUDY POPULATION AND IMAGING ANALYSIS. The study population, device, procedure, and definitions were previously described (4,9,10) (Online Tables 1   and 2 ). An independent core laboratory analyzed angiographic assessment, vasomotion test, IVUS grayscale, echogenicity, IVUS-based radiofrequency backscattering, and OCT, and their methodology has been extensively described (12) . OCT, in the early days of its clinical use, was not available in each investigating center. A protocol amendment was planned to allow an imaging follow-up to take place at 60 months. All patients were requested to sign this additional informed consent. However, the national regulatory bodies in France and Germany did not agree with the implementation of this amendment. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Serruys and Ormiston are principal and co-principal investigators.
METHODS
Manuscript received October 1, 2015; revised manuscript received October 26, 2015, accepted November 11, 2015. There were no differences between the group of patients with serial angiography (n ¼ 53) and the other group (n ¼ 48) in baseline demographic or lesion characteristics, with the exception of a lower incidence of patients presenting initially with unstable angina in the group with serial angiographic follow-up (7.5% vs. 22.9%, p ¼ 0.03; Online Table 2 ). after the procedure to 6.98, 7.01, and 5.54 mm 2 at 6, 24, and 60 months, respectively. GW ¼ guide wire; IVUS ¼ intravascular ultrasound;
LA ¼ lumen area; OCT ¼ optical coherence tomography; PA ¼ plaque area.
Serruys et al. In cohort B1, after 6 months, there was an increase in mean lumen area that became significant between 6 and 24 months (þ9.66%; p ¼ 0.015), as well as be- Figure 2E . 8.0%
Δ0.9%
Number of patients at Risk Approximately 50% of the reduction in hyper-and upper-echogenicity area was observed at 36 months, followed by a further 25% reduction between 36 and 60 months. The remaining 25% must correspond to permanent native dense calcium.
OCT POST-PROCEDURE AT 6, 12, 24, 36, AND 60
MONTHS. At the onset of the trial, the OCT investigation was not available in every investigational center. Between 6 and 60 months follow-up, there were 13 (B1) and 16 (B2) serial OCT measurements. On OCT, the struts were no longer discernable at 60 months ( Figure 3) ; thus, eventually only lumen area could be measured.
In Cohort B1, there were significant decreases in mean and minimum lumen area from baseline to 24 Figure 2D ).
DISCUSSION
The main findings of the study are the following:
1. The MACE rate at 60 months was 11.0%, with no definite/probable scaffold thrombosis. 
